Memphis drug developer announces $48.5 private placement
September 26, 2017 at 15:58 PM EDT
The biotech company will use the funds for its primary development program for treating stress urinary incontinence.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|